FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, specifically to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for reducing the rate of transmission of influenza virus infection, wherein the compound or a pharmaceutically acceptable salt thereof is administered to a null patient infected with the influenza virus.
EFFECT: use of the invention enables to effectively reduce the rate of transmission of influenza virus infection from an infected patient to a healthy person, preventing the spread of viral infection.
49 cl, 18 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS | 2013 |
|
RU2661408C2 |
| NOVEL 2-(IMIDAZOL-4-YL)-ETHANAMIDE PENTANEDIOIC-1,5 ACID COMPOSITIONS FOR TREATING AND PREVENTING VIRAL DISEASES | 2020 |
|
RU2746692C1 |
| H7N9 INFLUENZA A THERAPY | 2015 |
|
RU2682049C2 |
| VACCINE COMPOSITION FOR NON-IMMUNISED INDIVIDUALS | 2013 |
|
RU2661407C2 |
| INTEGRATED SYSTEM OF COLLECTION AND ANALYSIS HEALTH STATUS INFORMATION | 2010 |
|
RU2628051C2 |
| USE OF A PHARMACEUTICAL COMPOSITION WITH ANTIOXIDANT, VIRUCIDAL, IMMUNOSTULATING, ANTIHYPOXIC AND ANTI-AGGREGANT EFFECT | 2023 |
|
RU2808445C1 |
| MODIFIED INFLUENZA VIRUS VACCINES | 2013 |
|
RU2552213C2 |
| COMPOSITION CONTAINING PEPTIDE AND VIRUS NEURAMINIDASE INHIBITOR | 2011 |
|
RU2596785C2 |
| MODIFIED INFLUENZA VIRUS FOR MONITORING AND INCREASING VACCINE EFFICACY | 2006 |
|
RU2420535C2 |
| METHOD TO APPLY MODIFIED FLU VIRUS | 2006 |
|
RU2480480C2 |
